News Releases

Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,

DEER PARK, Ill. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of its common stock at

DEER PARK, Ill. , July 24, 2018 /PRNewswire/ -- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, announced positive  top-line results for its phase III study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free formulation for the treatment